Omeros (NASDAQ:OMER) Shares Gap Down – What’s Next?

Omeros Co. (NASDAQ:OMER) gapped down prior to trading on Monday . The stock had previously closed at $11.68, but opened at $11.28. Omeros shares last traded at $10.79, with a volume of 214,863 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have issued reports on OMER shares. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Thursday, December 19th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Rodman & Renshaw began coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

The company has a market capitalization of $605.58 million, a price-to-earnings ratio of -4.52 and a beta of 1.97. The firm has a 50-day moving average price of $7.73 and a two-hundred day moving average price of $5.43.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its stake in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares in the last quarter. MML Investors Services LLC grew its position in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 3,000 shares during the period. SPC Financial Inc. acquired a new position in shares of Omeros during the 3rd quarter worth about $77,000. SG Americas Securities LLC bought a new stake in shares of Omeros in the 3rd quarter valued at about $80,000. Finally, AQR Capital Management LLC acquired a new stake in Omeros in the 2nd quarter valued at about $105,000. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.